Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGylated recombinant human growth hormone with or without triptorelin in pubertal adolescent growth hormone deficiency
ChiCTR2200064385Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2022
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peg-somatropin and triptorelin in growth hormone deficiency (GHD) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Predicted adult height. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
peg-somatropintriptorelin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on ChiCTR2200064385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064385.